Screener
Pliant Therapeutics
PLRXPliant Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel therapies for the treatment of fibrosis.
$66.26M-26.1%
Earnings
Next report
Nov 5, 2026 (in 2 months)EPS estimate-$0.37
Competitors
Profile
Pliant Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel therapies for the treatment of fibrosis. The company leverages an integrin-based therapeutic platform to target the key biological drivers of fibrotic diseases, aiming to provide disease-modifying treatments for patients with high unmet medical needs.
Competitive position
A clinical-stage innovator specializing in the unproven but high-potential field of integrin-based therapeutics for fibrosis.
GeographiesUnited States, China
Customer segmentsClinical trial participants, Strategic partners
Business modelR&D intensive, Licensing and collaborations
SuppliersSingle-source raw material suppliers, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Biological material providers
CustomersClinical trial sites, Academic medical centers, Potential future pharmaceutical distributors
CountryUnited States of America
Listed2020
Employees158.0
CEOBernard Coulie
SectorHealthcare
IndustryBiotechnology
Websitepliantrx.com
FilingsSEC EDGAR
FAQ
- What is Pliant Therapeutics's market cap?
- Pliant Therapeutics (PLRX) has a market capitalization of $66.3M and trades on NASDAQ.
- Who are Pliant Therapeutics's competitors?
- Pliant Therapeutics's key competitors include Gilead Sciences, Rein Therapeutics, Inc. Common Stock, vTv Therapeutics Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Pliant Therapeutics headquartered?
- Pliant Therapeutics is headquartered in United States of America and employs approximately 158 people. It has been publicly traded since 2020.